$960M Expanded Drug Delivery Technology Offers New Subcutaneous Option for Biologics

Halozyme Therapeutics and Antares Pharma recently announced that they have reached an agreement whereby Halozyme will acquire Antares for approximately $960 million for its "best-in-class" potential auto-injector platform

Halozyme is developing a subcutaneous delivery technology for biologics called ENHANZE

▲Introduction to ENHANZE technology (Image source: Halozyme official website)

Antares Pharma is developing an auto-injector technology platform that allows patients to self-inject a variety of auto-injectors, already used for subcutaneous or intramuscular injection of a variety of drugs

▲A variety of automatic injectors developed by Antares (Image source: Halozyme official website)

The volume of liquids injected by Antares on the auto-injector platform may be further improved in the future, and in combination with Halozyme's ENHANZE technology, it can provide delivery options for small and large molecule products

Dr.

References:

[1] Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader.